Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (clinicaltrials.gov) - Oct 16, 2026 - P1 | N=152 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2026 ➔ Jul 2027 | Trial primary completion date: Sep 2026 ➔ Jul 2027
IO biomarker • Trial completion date • Trial primary completion date • Bladder Cancer • Clear Cell Renal Cell Carcinoma • Endocrine Cancer • Genito-urinary Cancer • Genitourinary Neuroendocrine Carcinoma • Kidney Medullary Carcinoma • Neuroendocrine Carcinoma • Oncology • Penile Cancer • Renal Cell Carcinoma • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Urethral Cancer • Urothelial Cancer • PD-L1
|